Stockscreener 앱 받기
9.67
2.76%
0.26
시장 영업 전:
9.67
Biocryst Pharmaceuticals Inc 주식(BCRX)의 최신 뉴스
Is Hiring AI-Focused Rare Disease R&D Leader Sandeep Menon Altering The Investment Case For BioCryst (BCRX)? - simplywall.st
Lilly to acquire CrossBridge Bio for up to $300m - Pharmaceutical Technology
Precision Trading with Biocryst Pharmaceuticals Inc. (BCRX) Risk Zones - Stock Traders Daily
BioCryst to File Peramivir NDA Supported by BARDA/HHS Funding - AOL.com
BCRX Should I Buy - Intellectia AI
BCRX.O Forecast — Price Prediction for 2026. Should I Buy BCRX.O? - Intellectia AI
BCRX.O Technical Analysis & Stock Price Forecast - Intellectia AI
BCRX.O PE Ratio & Valuation, Is BCRX.O Overvalued - Intellectia AI
Free cash flow per share of BioCryst Pharmaceuticals, Inc. – DUS:BO1 - TradingView — Track All Markets
BCRX PE Ratio & Valuation, Is BCRX Overvalued - Intellectia AI
BCRX Stock Price, Quote & Chart | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
BioCryst (BCRX) rallies 7.10% on acquisition buzz - MSN
BioCryst To Acquire Astria Therapeutics In $700M Deal - MSN
Aberdeen Group Boosts Stake in BioCryst Pharmaceuticals - National Today
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New R&D Leadership Appointment - Sahm
R&D Leadership Shake-Up at BioCryst (BCRX) Could Be A Game Changer For Its Pipeline Strategy - Sahm
BioCryst (BCRX) Chief R&D Officer receives large stock option and RSU inducement grants - Stock Titan
Sandeep Menon of BIOCRYST PHARMACEUTICALS (BCRX) submits Form 3 - Stock Titan
RBC Capital Adjusts BioCryst Pharmaceuticals PT to $14 From $13, Maintains Outperform Rating - Moomoo
New Strong Buy Stocks for June 25th - MSN
BioCryst (BCRX) soars 13% on acquisition buzz - MSN
BIOCRYST PHARMACEUTICALS INC (BCRX) Fundamental Analysis & Valuation - ChartMill
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6%Here's What Happened - MarketBeat
BioCryst names Sandeep Menon as chief R&D officer By Investing.com - Investing.com Canada
BioCryst Pharmaceuticals Appoints Dr. Sandeep M. Menon as Chief Research and Development Officer - Quiver Quantitative
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer - The Manila Times
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Operating cash flow per share of BioCryst Pharmaceuticals, Inc. – DUS:BO1 - TradingView — Track All Markets
BioCryst taps AMVUTTRA, PAXLOVID veteran to lead R&D effort - Stock Titan
BioCryst Pharmaceuticals, Inc. (BCRX) stock price, news, quote and history - Yahoo Finance Singapore
BioCryst stock jumps after hours on big pharma suitor buzz — retail sentiment hits 2026 peak - MSN
How The BioCryst Pharmaceuticals (BCRX) Narrative Is Shifting With Astria Deal And FY26 Targets - Yahoo Finance
BCRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BioCryst Pharmaceuticals Inc (BO1.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Technical Reactions to BCRX Trends in Macro Strategies - Stock Traders Daily
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
12 new BioCryst hires receive stock awards tied to 157,300 shares - Stock Titan
Investors Purchase High Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
BCRX Forecast, Price Target & Analyst Ratings | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
BioCryst Pharmaceuticals Stock: Navigating Biotech Innovation and Investor Opportunities in Rare Dis - AD HOC NEWS
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co. - MarketBeat
Rate Cut: Is BioCryst Pharmaceuticals Inc subject to activist investor interest2026 Momentum & Reliable Breakout Stock Forecasts - baoquankhu1.vn
1.06%
1.05%
자본화:
|
볼륨(24시간):